VIRGINIA RETIREMENT SYSTEMS ET Al Sells 247,600 Shares of Edwards Lifesciences Corporation $EW

VIRGINIA RETIREMENT SYSTEMS ET Al lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 26.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 675,711 shares of the medical research company’s stock after selling 247,600 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Edwards Lifesciences were worth $57,604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP bought a new stake in Edwards Lifesciences in the third quarter worth about $238,688,000. Jennison Associates LLC lifted its stake in Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Edwards Lifesciences by 114.5% in the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock worth $161,055,000 after purchasing an additional 1,111,139 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on EW shares. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research note on Friday, April 24th. Evercore reissued an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $95.65.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,782,941.44. This trade represents a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 88,096 shares of company stock valued at $7,288,799 over the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $79.69 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The firm’s 50 day moving average price is $81.78 and its 200-day moving average price is $82.80. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89. The company has a market cap of $45.88 billion, a PE ratio of 42.39, a P/E/G ratio of 1.94 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.